1. Gene targeting: Roadmap to future therapies

   • Lars C. Huber
   • Thomas Pap
   • Steffen Gay

   Invited Commentary Pages: 323 - 325

2. Web alert

   News Pages: 326 - 327

3. Literature alert

   Abstract Pages: 328 - 329

4. Etanercept and methotrexate combination in rheumatoid arthritis

   • Larry Moreland

   Clinical Trials Report Pages: 333 - 333

5. Adalimumab in rheumatoid arthritis

   • Larry Moreland

   Clinical Trials Report Pages: 333 - 334

6. Infliximab in rheumatoid arthritis

   • Larry Moreland

   Clinical Trials Report Pages: 334 - 335

7. Targeting cytokines beyond tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis

   • Iain B. McInnes
   • J. Alastair Gracie

   OriginalPaper Pages: 336 - 342

8. Update on autoantibodies in rheumatoid arthritis

   • S. Louis Bridges Jr.

   OriginalPaper Pages: 343 - 350

9. Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis

   • Tobias Kurth
   • Charles H. Hennekens
   • J. Michael Gaziano

   OriginalPaper Pages: 351 - 356

10. B cells: New ways to inhibit their function in rheumatoid arthritis

    • Robert H. Carter

    OriginalPaper Pages: 357 - 363

11. Occupational and environmental exposures as risk factors for systemic lupus erythematosus

    • Glinda S. Cooper
    • Christine G. Parks

    OriginalPaper Pages: 367 - 374

12. New advances in measurement of complement activation: Lessons of systemic lupus erythematosus

    • Chau-Ching Liu
    • Susan Manzi
    • Joseph M. Ahearn

    OriginalPaper Pages: 375 - 381

13. Biomarkers in systemic lupus erythematosus

    • Gabor G. Illei
    • Peter E. Lipsky

    OriginalPaper Pages: 382 - 390

14. Current advances in the human lupus genetics

    • Nan Shen
    • Betty P. Tsao

    OriginalPaper Pages: 391 - 398